Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ligand divests product lines
September 18, 2006
| A version of this story appeared in
Volume 84, Issue 38
Ligand Pharmaceuticals has signed two deals under which it is selling its commercial drug portfolio to focus on its research efforts. Ligand is selling U.S. and Canadian rights to its morphine sulfate pain therapy Avinza to King Pharmaceuticals for $313 million. King will make unspecified royalty payments until Avinza's patent expires in 2017. Ligand also agreed to sell its oncology product line to Eisai for $205 million. Eisai will make royalty payments as well.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X